Major depressive disorder, often called MDD, is one of the most serious and common mental health conditions in the world.
People with this condition often experience a long-lasting low mood, feelings of hopelessness, loss of interest in daily life, and difficulty enjoying things they once liked. Depression can also affect sleep, appetite, energy levels, and concentration. For many people, these symptoms can make work, relationships, and daily activities very difficult.
Fortunately, there are medications that can help treat depression. However, finding the right medication for each person can be challenging.
Doctors usually need to try different medicines to see which one works best for a patient. This process can take months, and during that time people may continue to suffer from symptoms or deal with unwanted side effects.
Two of the most commonly prescribed types of antidepressants are called selective serotonin reuptake inhibitors, or SSRIs, and serotonin-norepinephrine reuptake inhibitors, known as SNRIs. These medications work by affecting chemicals in the brain that help regulate mood and emotions.
SSRIs increase levels of serotonin, a chemical messenger that helps control mood, sleep, digestion, and appetite. Many well-known antidepressants belong to this group.
SNRIs work in a similar way but influence two brain chemicals instead of one. In addition to serotonin, they increase levels of norepinephrine, another messenger that affects alertness, attention, and mood.
Even though both types of medications are widely used and effective for many people, doctors still do not fully understand why some patients respond better to SSRIs while others improve more with SNRIs.
Because of this uncertainty, patients often need to go through a long trial-and-error process before finding the medication that works best for them.
A new study conducted by researchers from Southeast University in Nanjing and the Affiliated Brain Hospital of Nanjing Medical University aimed to better understand why different patients respond differently to these treatments. The team explored whether the answer might lie in how different parts of the brain are connected.
Their findings were published in the scientific journal Molecular Psychiatry.
The researchers focused on two important brain areas. One is the frontal lobe, which sits in the front part of the brain and plays a major role in decision-making, planning, and controlling emotions. The other is the amygdala, a small structure deep inside the brain that helps process emotions such as fear, stress, and happiness.
These two brain regions communicate with each other through networks of nerve fibers known as white matter connections. Scientists believe that these connections help regulate emotional responses and mood.
To study these connections, the researchers examined brain scans from 106 people who had been diagnosed with major depressive disorder. Some of the patients had improved after taking SSRI medications, while others had responded better to SNRIs.
The scientists used a brain imaging technique called diffusion tensor imaging, or DTI. This method tracks how water molecules move through the brain, allowing researchers to map the pathways of white matter fibers that connect different brain regions.
By analyzing these brain scans, the researchers discovered that the strength of connections between the frontal lobe and a specific part of the amygdala was different in patients who responded to different medications.
In particular, they found that connections between the frontal lobe and the medial nucleus of the amygdala could help predict which medication a person was more likely to benefit from. People who responded well to SSRIs showed different patterns in this brain connection compared with those who improved with SNRIs.
The researchers also discovered that these brain connection patterns matched differences in the brain’s chemical systems. The pathways appeared to relate to the serotonin and norepinephrine systems that the medications target.
In addition, genetic factors seemed to play a role. Certain genetic differences related to the serotonin transporter gene were linked to the brain connection patterns and the type of medication that worked best for patients.
Together, these findings suggest that a person’s brain wiring, brain chemistry, and genetics may all influence how well they respond to different antidepressant medications.
The researchers hope that this discovery could lead to better ways of choosing treatments for depression in the future. Instead of relying only on trial and error, doctors might eventually use brain scans and genetic information to help predict which medication will work best for a patient.
This approach could make treatment faster and more effective. Patients might recover sooner and avoid the frustration of trying several medications that do not work for them.
Although more research is needed before this method can be used in everyday medical practice, the study offers an exciting step toward personalized mental health care.
By better understanding how the brain works in depression, scientists hope to improve treatment strategies and help more people regain their emotional well-being.
If you care about mental health, please read studies about how dairy foods may influence depression risk, and 6 foods you can eat to improve mental health.
For more mental health information, please see recent studies about top foods to tame your stress, and Omega-3 fats may help reduce depression.
Copyright © 2026 Knowridge Science Report. All rights reserved.
